Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease
The growth of the global benign prostatic hyperplasia therapeutics market is majorly driven by the increase in male geriatric population. Other factors boosting the market growth include rise in awareness about prostate cancer and other urological disorders and increase in occurrence of benign prostatic hyperplasia patients across the world. However, inclination of patients toward minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hampers the market growth. Conversely, presence of strong pipeline products and high potential in untapped markets of the emerging economies are expected to provide lucrative growth opportunities for the global benign prostatic hyperplasia therapeutics market.
In 2018, the global Benign Prostatic Hyperplasia Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Benign Prostatic Hyperplasia Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Benign Prostatic Hyperplasia Therapeutics development in United States, Europe and China.
The key players covered in this study
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH & Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited
Market segment by Type, the product can be split into
Alpha blocker
5-Alpha reductase inhibitor
Phosphodiesterase-5 inhibitor
Others
Market segment by Application, split into
Mono drug therapy
Combination drug therapy
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Benign Prostatic Hyperplasia Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Benign Prostatic Hyperplasia Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Benign Prostatic Hyperplasia Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Summary:
Get latest Market Research Reports on Benign Prostatic Hyperplasia Therapeutics . Industry analysis & Market Report on Benign Prostatic Hyperplasia Therapeutics is a syndicated market report, published as Global Benign Prostatic Hyperplasia Therapeutics Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Benign Prostatic Hyperplasia Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.